Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19

医学 重症监护室 肝素 随机对照试验 加药 凝血病 随机化 低分子肝素 肾功能 败血症 内科学 麻醉
作者
Alex C. Spyropoulos,Mark Goldin,Dimitrios Giannis,Wassim Diab,Janice Wang,Sameer Khanijo,Andrea Mignatti,Eugenia Gianos,Marc Cohen,Gulru Sharifova,Jeet Lund,Alfonso Tafur,Paul A. Lewis,Kevin P. Cohoon,Husneara Rahman,Cristina Sison,Martin Lesser,Kanta Ochani,Nirav Agrawal,Judith Hsia,Victoria E. Anderson,Marc P. Bonaca,Jonathan L. Halperin,Jeffrey I. Weitz,Lori Ohanesian,Michelle Glater,Christopher C.K. Ho,Annamaria Iakovou,Daniel Ying,Manile Dastagir,Alex Convissar,Seerat Aujla,Elizabeth Mathew,Vani Thiyagarajan,Tricia Lewis,Luis Gruberg,Paul Maccaro,Dana Kuziw,Bhumi Pandhi,George Surguladze,Ashley M. Eapen,A. Pantea,Phyllis Suen,John P. Flynt,Michael Krzyzak,Kamal Sharma,Amanda Steadham,Sherry McLean,Karen Herring,Karen Maroney,Kambiz Zorriasateyn,B. Vargas,Marisa Durante,Ujala Bhokary,Linda Pierchala,Elizabeth A. Fisher,Debi L. Oxenberg,Alison Sabados,Omair A. Chaudhary,Shelley Schultz,S. Cotey,Connie N. Hess,Hope Cruse,Daniel Uy,Sunita Sharma,Kevin Molina,Daliya Jagat,Bandyopadhyay Dehali
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:181 (12): 1612-1612 被引量:330
标识
DOI:10.1001/jamainternmed.2021.6203
摘要

Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown.To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US.Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status.The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data.Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71).In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients.ClinicalTrials.gov Identifier: NCT04401293.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Ji发布了新的文献求助10
2秒前
嘟嘟呀是只小泰迪完成签到,获得积分10
3秒前
oneming发布了新的文献求助10
3秒前
今后应助魔幻山芙采纳,获得10
3秒前
科目三应助linda627采纳,获得10
4秒前
NexusExplorer应助诚心的方盒采纳,获得10
4秒前
英姑应助YI点半的飞机场采纳,获得10
4秒前
4秒前
5秒前
6秒前
小羊爱吃蓝莓完成签到,获得积分10
6秒前
可爱的函函应助青柠采纳,获得10
7秒前
兔子吃胡萝卜完成签到,获得积分10
8秒前
9秒前
滑翔的咸鱼完成签到 ,获得积分10
9秒前
思源应助挺帅一男的采纳,获得10
9秒前
scl完成签到,获得积分10
10秒前
10秒前
小鱼发布了新的文献求助10
10秒前
巫雁发布了新的文献求助10
11秒前
lzr关闭了lzr文献求助
11秒前
linda627完成签到,获得积分10
13秒前
Ji完成签到,获得积分10
14秒前
15秒前
15秒前
15秒前
15秒前
有星星的小路完成签到,获得积分10
15秒前
16秒前
搜集达人应助金熙美采纳,获得10
16秒前
挺帅一男的完成签到,获得积分10
17秒前
灰灰发布了新的文献求助10
17秒前
linda627发布了新的文献求助10
19秒前
匹诺曹完成签到,获得积分10
19秒前
青柠发布了新的文献求助10
20秒前
21秒前
21秒前
21秒前
gongyanqing完成签到,获得积分10
21秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135007
求助须知:如何正确求助?哪些是违规求助? 2785964
关于积分的说明 7774560
捐赠科研通 2441787
什么是DOI,文献DOI怎么找? 1298183
科研通“疑难数据库(出版商)”最低求助积分说明 625088
版权声明 600825